Consensus Cadrenal Therapeutics, Inc.

Equities

CVKD

US1276361086

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-10 pm EDT			5-day change	1st Jan Change
0.46 ^USD	-5.23%		-6.22%	-37.83%

May. 09	Cadrenal Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 09	Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts	CI

Evolution of the average Target Price on Cadrenal Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

84f404fc77d36fcc1dc17597573b.26A9TSrCKjb6IBuD_PRJoQcKgnZBHGBoJK7-Y-2vPKw.rPJYfV_6bUDIbFbBvbM94Et85QIoUlkYXOPMUL3bc-qU8VgeefFAYI5vWg~cbc2f386a35fdd51b4a36a04c04795fd

Analyst Recommendations on Cadrenal Therapeutics, Inc.

Noble Capital Starts Cadrenal Therapeutics With Outperform Rating, $4 Price Target	Dec. 18	MT
HC Wainwright Initiates Cadrenal Therapeutics With Buy Rating	Nov. 20	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.46 USD

Average target price

3.5 USD

Spread / Average Target

+660.87%

High Price Target

4 USD

Spread / Highest target

+769.57%

Low Price Target

3 USD

Spread / Lowest Target

+552.17%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Cadrenal Therapeutics, Inc.

Noble Capital
HC Wainwright

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar